1. Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;
2. Norwegian Cancer Genomics Consortium, Oslo, Norway;
3. K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway;
4. Massachusetts General Hospital Cancer Center, Boston, MA;
5. Department of Pathology, Harvard Medical School, Charlestown, MA;
6. Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;
7. Institute of Clinical Medicine, Faculty of Medicine,
8. Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, and
9. Department of Informatics, University of Oslo, Oslo, Norway;
10. Department of Pathology and
11. Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;
12. Department of Oncology, Helsinki University Hospital Cancer Center, Helsinki, Finland;
13. Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland;
14. Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;
15. Department for Clinical Science, University of Bergen, Bergen, Norway; and
16. Broad Institute of Harvard and MIT, Cambridge, MA;
17. Department of Oncology, Oslo University Hospital, Oslo, Norway